Pediatric Brain Tumor Clinical Trials

Questions about patients' participation in the following clinical trials can be directed to the study coordinator at (415) 353-9387 or a nurse practitioner at (415) 514-0238.

Newly Diagnosed Tumor


Ependymoma
Phase 3 Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma, Ages 1 to 21 years (Childrens Oncology Group Study ACNS0831). Clinicaltrials.gov Overview

Diffuse Intrinsic Pontine Glioma
Molecular Profiling for Individualized Treatment Plan for Diffuse Intrinsic Pontine Glioma (Pacific Pediatric Neuro-Oncology Consortium Study PNOC 003). PNOC Overview

[ENROLLMENT PENDING] Convection Enhanced Delivery (CED) with Irinotecan Liposome Injection Using Real Time Imaging in Children with DIPG (Pacific Pediatric Neuro-Oncology Consortium Study PNOC 009). Clinicaltrials.gov Overview

A Phase 1 Study of AZD1775 (MK-1775, IND# 116495) Concurrent with Local Radiation Therapy for the Treatment of Newly Diagnosed Children with Diffuse Pontine Gliomas (Children’s Oncology Group Study ADVL1217)

Recurrent Disease


Medulloblastoma and Primitive Neural Ectodermal Tumor (PNET) 
Modified Measles Virus (MV-NIS) for Children and Young Adults with Recurrent Medulloblastoma or Recurrent Atypical Teratoid/Rhabdoid Tumors (ATRT; Pacific Pediatric Neuro-Oncology Consortium Study PNOC 005). PNOC Overview

Phase 1 Study of Pazopanib in Combination with Irinotecan and Temozolomide (PAZIT) for Children and Young Adults with Relapsed or Refractory Sarcoma (UCSF)

A Phase 1/2 Study of AZD1775 (MK-1775, IND# 121422) in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors (Children’s Oncology Group Study ADVL1312)

Recurrent Glioma
Safety, Phase 0, and Pilot Efficacy Study of Vemurafenib, an Oral Inhibitor of BRAFV600E, in Children with Recurrent/Refractory BRAFV600E-mutant gliomas (Pacific Pediatric Neuro-Oncology Consortium Study PNOC 002). PNOC Overview

Selumetinib in Treating Young Patients with Recurrent or Refractory Low-Grade Glioma (Pediatric Brain Tumor Consortium Study 029). Clinicaltrials.gov Overview

A Phase 1 study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors (Children’s Oncology Group Trial ADVL1416). Clinicaltrials.gov Overview

A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors and Lymphoma (Children’s Oncology Group Study ADVL1312)

A Phase 1/2 Study of Pembrolizumab MK-3475 in Children with Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma KEYNOTE-051 (Children’s Oncology Group Study ADVL1621)

A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects with Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma (Epizyme, Inc. Study EZH-102)

A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors (Ignyta, Inc. Study Ignyta RXDX-101-03)


Trials Studying Late Effects of Treatment

Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with Cancer (Children's Oncology Group Trial ALTE07C1). Study Details


Trials Studying Novel Neuroimaging Techniques

Pilot Study of Safety and Toxicity of Acquiring Hyperpolarized Carbon-13 Imaging in Children With Brain Tumors. (Pacific Pediatric Neuro-Oncology Consortium Study 011). PNOC Overview